GlassScriptPhysician profile
Julie Chew
NPI 1598589392
$1,500.46
in general payments reported to CMS, 2019-2025
19 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $329.26 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $185.66 | 2025 | Cobenfy |
| Abbvie INC. | $164.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $135.25 | 2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.61 | 2025 | Caplyta |
| Tris Pharma INC | $84.05 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $79.75 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $55.74 | 2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $45.98 | 2025 | Aristada, Lybalvi |
| Braeburn INC. | $45.20 | 2025 | Brixadi |
| Lundbeck LLC | $44.60 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $41.71 | 2025 | |
| Noven Therapeutics, LLC | $40.75 | 2025 | Xelstrym |
| Janssen Pharmaceuticals, INC | $35.70 | 2025 | Spravato |
| Corium, LLC | $32.03 | 2025 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $23.73 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $15.78 | 2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2025 | Trintellix |
| Bausch Health US, LLC | $13.79 | 2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Chew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.